MMAF

Item no.	HY-15579-100mg
Manufacturer	MedChem Express
CASRN	745017-94-1
Amount	100 mg
Quantity options	100 mg 10 mg 25 mg 2 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	99.94
Citations	[1]Doronina SO, et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem. 2006 Jan-Feb;17(1):114-24.\|[2]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16(9):2562-70.\|[3]Lee JJ, et al. Enzymatic prenylation and oxime ligation for the synthesis of stable and homogeneous protein-drug conjugates for targeted therapy. Angew Chem Int Ed Engl. 2015 Oct 5;54(41):12020-4.\|[4]Kim EG, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted CancerTherapeutics. J Control Release. 2018 May 10;277:48-56.\|Mol Cancer Ther. 2023 Jan 31;MCT-22-0440.\|Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236.\|Patent. US20210393733A1.\|Research Square Preprint. 2023 Dec 4.\|Research Square Print. 2023 Jan 6th.\|Target Oncol. 2019 Oct;14(5):577-590.\|University of Minnesota. 2022 Sep.\|Oncol Rep. 2020 Dec 9.
Smiles	CC(C)[C@H](NC)C(N[C@H](C(N([C@@H]([C@@H](C)CC)[C@H](OC)CC(N1CCC[C@@]1([H])[C@H](OC)[C@@H](C)C(N[C@H](C(O)=O)CC2=CC=CC=C2)=O)=O)C)=O)C(C)C)=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	Monomethylauristatin F
Shipping Condition	Room temperature
Available
Manufacturer - Type	ADC Related
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	ADC Cytotoxin; Microtubule/Tubulin
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	731.96
Product Description	MMAF (Monomethylauristatin F) is a potent tubulin polymerization inhibitor and is used as a antitumor agent. MMAF (Monomethylauristatin F) is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) such as vorsetuzumab mafodotin and SGN-CD19A[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 140 mg/mL (ultrasonic)
Manufacturer - Pathway	Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton
Isoform	Auristatin
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15579-100mg-safety-datasheet.pdf